This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.
Alliance Global Partners Reaffirms Their Buy Rating on Cybin (CYBN)
In a report released on November 14, James Molloy from Alliance Global Partners reiterated a Buy rating on Cybin, with a price target of $30.00. The company’s shares closed last Friday at C$0.14.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Molloy covers the Healthcare sector, focusing on stocks such as Pelthos Therapeutics, Talphera, and Imunon. According to TipRanks, Molloy has an average return of -26.0% and a 23.12% success rate on recommended stocks.
Cybin has an analyst consensus of Strong Buy, with a price target consensus of $41.33, a 30,514.81% upside from current levels. In a report released today, H.C. Wainwright also reiterated a Buy rating on the stock with a $55.00 price target.
CYBN market cap is currently C$1.92M and has a P/E ratio of -0.02.
Read More on CYBN:
This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
